Article Text

other Versions

PDF
Original research
Preoperative staging of cholangiocarcinoma and biliary carcinoma using 18F-fluorodeoxyglucose positron emission tomography: a meta-analysis
  1. Jing-Hong Hu1,
  2. Jui-hsiang Tang2,
  3. Cheng-Hui Lin3,4,
  4. Yin-Yi Chu3,4,
  5. Nai-Jen Liu3,4
  1. 1Department of Gastroenterology and Hepatology, Department of Internal Medicine, Chang Gung Memorial Hospital, Yunlin, Taiwan
  2. 2Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University Hospital, Taipei, Taiwan
  3. 3Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou, Taiwan
  4. 4Department of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan
  1. Correspondence to Dr Nai-Jen Liu, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou, Taiwan and Department of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan; launaijn.tw{at}yahoo.com.tw

Abstract

This meta-analysis was performed to determine the diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) in assessing primary cholangiocarcinoma (CCA) and CCA with lymph node and distant metastasis. A literature search for studies reporting the use of 18F-FDG-PET for preoperative work-up/staging in patients with CCA was performed. Diagnostic OR (DOR) was used as an index of diagnostic performance of FDG-PET/CT in predicting primary CCA, lymph node metastases, and distant metastases. The pooled DOR was 9.34 (95% CI 4.27 to 20.42) and the area under the summary receiver operating characteristic (SROC) curve was 0.8643 (SE=0.0362), indicating overall good discriminatory test performance in predicting primary CCA. Subgroup analyses based on the primary tumor site showed better diagnostic performance for intrahepatic CCA (DOR=54.44, 95% CI 13.44 to 220.49), both intrahepatic and extrahepatic CCA (DOR=32.96, 95% CI 1.41 to 768.80) and gallbladder cancer (DOR=12.93, 95% CI 1.97 to 84.80), than for extrahepatic CCA (DOR=2.55, 95% CI 0.71 to 9.20) and hilar CCA (DOR=2.75, 95% CI 0.17 to 43.72). The pooled DOR for the prediction of lymph nodes metastases in 10 studies was 11.34 (95% CI 4.79 to 26.80), with moderate heterogeneity (Cochran Q=15.14, p=0.0872, I2=40.5%). The area under the SROC curve was 0.8584 (SE=0.0729). In conclusion, 18F-FDG-PET and PET/CT were found to be accurate in the evaluation of primary tumors, lymph node metastasis, and distant metastasis in patients with CCA.

  • meta-analysis
  • lymph node metastasis
  • cholangiocarcinoma
  • 18F-FDG-PET

Statistics from Altmetric.com

Footnotes

  • Contributors J-HH: study concepts, study design, definition of intellectual content, clinical studies, experimental studies, data acquisition, data analysis, statistical analysis and manuscript preparation. J-T: definition of intellectual content, literature research, data acquisition, data analysis and statistical analysis. C-HL: literature research and manuscript editing. Y-YC: study design and clinical studies. N-JL: guarantor of integrity of the entire study, manuscript editing and manuscript review. All authors have read and approved the final version to be submitted.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.